| Nov 1 |
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
|
| Oct 31 |
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
|
| Oct 23 |
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc
|
| Oct 14 |
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
|
| Oct 9 |
Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
| Oct 7 |
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
|
| Sep 25 |
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
|
| Aug 17 |
Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 15 |
Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript
|
| Aug 15 |
Biofrontera GAAP EPS of -$0.05 beats by $0.67, revenue of $7.84M beats by $0.38M
|
